Rhoen Klinikum (RHK) H2 2025 earnings summary

Executive summary

• Revenues increased by 6.8% to €1,704.7 million, driven by higher inpatient and semi-inpatient treatments and a 2.8% rise in patient numbers to 938,650.

• EBITDA declined by 4.4% to €105.9 million due to higher material and personnel costs and the end of energy cost reimbursements.

• Consolidated profit fell by €8.9 million to €36.3 million, impacted by higher depreciation and a lower finance result.

• The group remains financially robust with a high equity ratio of 74.3% and net liquidity of €207.7 million.

• Strategic investments continued in digitalisation, facility modernisation, and sustainability initiatives.

Financial highlights

• Revenues: €1,704.7 million (+6.8% year-over-year).

• EBITDA: €105.9 million (-4.4% year-over-year).

• EBIT: €40.9 million (-15.0% year-over-year).

• Consolidated profit: €36.3 million (-19.7% year-over-year).

• Earnings per share: €0.52 (previous year: €0.65).

• Net liquidity: €207.7 million (down from €259.9 million).

• Equity ratio: 74.3%.

• Investments: €112.4 million (up from €73.5 million).

Outlook and guidance

• For 2026, revenues are expected at €1.7 billion (±5%), with EBITDA forecast between €110 million and €125 million.

• Moderate improvement in case numbers and cost weights anticipated.

• Continued focus on digitalisation, outpatient expansion, and energy efficiency.

• Regulatory and macroeconomic uncertainties remain significant.